Bio-Techne Corporation or Sarepta Therapeutics, Inc.: Who Leads in Yearly Revenue?

Biotech Revenue Showdown: Bio-Techne vs. Sarepta

__timestampBio-Techne CorporationSarepta Therapeutics, Inc.
Wednesday, January 1, 20143577630009757000
Thursday, January 1, 20154522460001253000
Friday, January 1, 20164990230005421000
Sunday, January 1, 2017563003000154584000
Monday, January 1, 2018642993000301034000
Tuesday, January 1, 2019714006000380833000
Wednesday, January 1, 2020738691000540099000
Friday, January 1, 2021931032000701887000
Saturday, January 1, 20221105599000933013000
Sunday, January 1, 202311367020001243336000
Monday, January 1, 20241159060000
Loading chart...

Unveiling the hidden dimensions of data

Bio-Techne vs. Sarepta: A Revenue Race in the Biotech Arena

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Bio-Techne Corporation and Sarepta Therapeutics, Inc. have been at the forefront of this race. Starting in 2014, Bio-Techne's revenue was approximately 37 times that of Sarepta's. However, Sarepta has shown remarkable growth, with its revenue increasing by over 12,000% by 2023, surpassing Bio-Techne for the first time.

Bio-Techne, with a steady growth trajectory, saw its revenue increase by over 220% from 2014 to 2023. Despite this, Sarepta's aggressive expansion strategy allowed it to close the gap and eventually take the lead. This shift highlights the competitive nature of the biotech industry, where innovation and strategic investments can rapidly alter market dynamics. As we look to the future, the question remains: can Bio-Techne reclaim its lead, or will Sarepta continue to dominate?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025